Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
Open Access
- 10 April 2025
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 83, 104473
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancernpj Breast Cancer, 2024
- Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancerESMO Real World Data and Digital Oncology, 2024
- A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab MonotherapyClinical Oncology, 2024
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsEuropean Journal of Cancer, 2024
- Real-World Evidence: A PrimerPharmaceutical Medicine, 2023
- Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?Cancer Treatment Reviews, 2022
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysisCancer Treatment Reviews, 2021
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillanceNature Reviews Clinical Oncology, 2019
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementCancer, 2018